The Molecular Landscape of Small Lymphocytic Lymphoma: Mechanisms and Therapeutic Approaches
DOI:
https://doi.org/10.58445/rars.2879Keywords:
Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, MYC, p53, BCL-2, Cytokine, Gene, Early Prognosis, DiagnosticsAbstract
Cancers such as Small Lymphocytic Lymphoma (SLL) and Chronic Lymphocytic Leukemia (CLL) are typically caused by a series of mutations within an individual’s genome. Genes such as TP53, BCL-2, and MYC are crucial in the progression of not only these diseases, but others too. Therefore, in developing therapies for these disorders, it is essential to understand the mutations and interactions of these genes at the molecular level. As a result, understanding the complex mechanisms and signaling pathways that connect the genes is paramount to developing treatments. Additionally, when investigating a cancer case, the pathology behind these cancers must be accurately interpreted for a proper diagnosis. Cytokines must also be understood as they are involved in the cell signaling process. Regarding treatments, comparing the effects of different drug combinations is necessary to determine the most effective treatment regimen. In addition to drug-based treatments, immunotherapies also prove effective. Despite these advanced technologies, diagnosing cancer early on is essential, as an early diagnosis significantly improves the chances of successful treatment and survival.
References
Ahmadi, Seyed Esmaeil, et al. “Myc: A Multipurpose Oncogene with Prognostic and Therapeutic Implications in Blood Malignancies.” Journal of Hematology & Oncology, U.S. National Library of Medicine, 9 Aug. 2021, pmc.ncbi.nlm.nih.gov/articles/PMC8351444/#Sec5.
Babamohamadi, Mehregan, et al. “Recent findings on the role of wild-type and mutant p53 in cancer development and therapy.” Frontiers in Molecular Biosciences, U.S. National Library of Medicine, 26 Sept. 2022, https://pubmed.ncbi.nlm.nih.gov/36225257/.
Bailly, Sarah, et al. “Targeting CD19 in Diffuse Large B-Cell Lymphoma: An Expert Opinion Paper.” Hematological Oncology, U.S. National Library of Medicine, 7 June 2022, pubmed.ncbi.nlm.nih.gov/35488888/.
Bartlett, Nancy L, et al. “Dose-Adjusted Epoch-R Compared with R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, U.S. National Library of Medicine, 20 July 2019, pmc.ncbi.nlm.nih.gov/articles/PMC6774813/.
Beaulieu, Marie-Eve, et al. “Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein.” Cells, U.S. National Library of Medicine, 22 Apr. 2020, pmc.ncbi.nlm.nih.gov/articles/PMC7226237/.
Bende, RJ, et al. “Molecular Pathways in Follicular Lymphoma.” Leukemia, U.S. National Library of Medicine, 12 Oct. 2006, pubmed.ncbi.nlm.nih.gov/17039231/.
Bolen, CR, et al. “Prognostic Impact of Somatic Mutations in Diffuse Large B-Cell Lymphoma and Relationship to Cell-of-Origin: Data from the Phase III Goya Study.” Haematologica, U.S. National Library of Medicine, 1 Sept. 2020, pubmed.ncbi.nlm.nih.gov/33054054/.
Brentjens, Renier J, et al. “Eradication of Systemic B-Cell Tumors by Genetically Targeted Human T Lymphocytes Co-Stimulated by CD80 and Interleukin-15.” Nature Medicine, U.S. National Library of Medicine, 10 Feb. 2003, pubmed.ncbi.nlm.nih.gov/12579196/.
Brudno, Jennifer N, and James N Kochenderfer. “Chimeric Antigen Receptor T-Cell Therapies for Lymphoma.” Nature Reviews. Clinical Oncology, U.S. National Library of Medicine, 31 Aug. 2017, pubmed.ncbi.nlm.nih.gov/28857075/.
Byrd, John C, et al. “Acalabrutinib versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, U.S. National Library of Medicine, 26 July 2021, pubmed.ncbi.nlm.nih.gov/34310172/.
Calin, GA, et al. “Frequent Deletions and Down-Regulation of Micro- RNA Genes Mir15 and MIR16 at 13q14 in Chronic Lymphocytic Leukemia.” Proceedings of the National Academy of Sciences of the United States of America, U.S. National Library of Medicine, 14 Nov. 2002, pubmed.ncbi.nlm.nih.gov/12434020/.
Candé, Celine, et al. “Apoptosis-Inducing Factor (AIF): Key to the Conserved Caspase-Independent Pathways of Cell Death?” Journal of Cell Science, U.S. National Library of Medicine, 15 Dec. 2002, pubmed.ncbi.nlm.nih.gov/12432061/.
Conacci-Sorrell, Maralice, et al. “An overview of MYC and its interactome.” Cold Spring Harbor Perspectives in Medicine, U.S. National Library of Medicine, 1 Jan. 2014, https://pubmed.ncbi.nlm.nih.gov/24384812/.
Davids, MS, et al. “Phase I First-in-Human Study of Venetoclax in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, U.S. National Library of Medicine, 17 Jan. 2017, pubmed.ncbi.nlm.nih.gov/28095146/.
DiGiuseppe, Joseph A, and Michael J Borowitz. “Clinical Utility of Flow Cytometry in the Chronic Lymphoid Leukemias.” Seminars in Oncology, U.S. National Library of Medicine, 25 Feb. 1998, pubmed.ncbi.nlm.nih.gov/9482521/.
Draeger, LJ, and G P Mullen. “Interaction of the bHLH-ZIP Domain of c-Myc with H1-Type Peptides. Characterization of Helicity in the H1 Peptides by NMR.” The Journal of Biological Chemistry, U.S. National Library of Medicine, 21 Jan. 1994, pubmed.ncbi.nlm.nih.gov/8294427/.
Egle, Alexander, et al. “Bim Is a Suppressor of Myc-Induced Mouse B Cell Leukemia.” Proceedings of the National Academy of Sciences of the United States of America, U.S. National Library of Medicine, 12 Apr. 2004, pubmed.ncbi.nlm.nih.gov/15079075/.
Fenu, Elena M., and Nancy S. Rosenthal. “Educational Case: Small Lymphocytic Lymphoma: Diagnostic Features and Prognosis.” Academic Pathology, U.S. National Library of Medicine, 21 Jan. 2020, https://pmc.ncbi.nlm.nih.gov/articles/PMC6974742/.
Gauthier, Jordan, and Cameron J Turtle. “Insights into Cytokine Release Syndrome and Neurotoxicity after CD19-Specific Car-T Cell Therapy.” Current Research in Translational Medicine, U.S. National Library of Medicine, 3 Apr. 2018, pubmed.ncbi.nlm.nih.gov/29625831/.
Geldres, Claudia, et al. “Chimeric Antigen Receptor-Redirected T Cells Return to the Bench.” Seminars in Immunology, U.S. National Library of Medicine, 12 Jan. 2016, pubmed.ncbi.nlm.nih.gov/26797495/.
Guerra, Lina, et al. “Myc is required for activation of the ATM-dependent checkpoints in response to DNA damage.” Public Library of Science One, U.S. National Library of Medicine, 27 Jan. 2010, https://pubmed.ncbi.nlm.nih.gov/20111719/.
Guo, Y, et al. “BCL2-Negative Follicular Lymphomas Frequently Have BCL6 Translocation and/or BCL6 or P53 Expression.” Pathology International, U.S. National Library of Medicine, 5 Mar. 2007, pubmed.ncbi.nlm.nih.gov/17295647/.
Gust, Juliane, et al. “Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 Car-T Cells.” Cancer Discovery, U.S. National Library of Medicine, 12 Oct. 2017, pubmed.ncbi.nlm.nih.gov/29025771/.
Hallek, Michael, et al. “IWCLL Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of Cll.” Blood, U.S. National Library of Medicine, 14 Mar. 2018, pubmed.ncbi.nlm.nih.gov/29540348/.
Hanada, M, et al. “Bcl-2 Gene Hypomethylation and High-Level Expression in B-Cell Chronic Lymphocytic Leukemia.” Blood, U.S. National Library of Medicine, 15 Sept. 1993, pubmed.ncbi.nlm.nih.gov/8104532/.
Hemann, M T, and S W Lowe. “The P53-Bcl-2 Connection.” Cell Death and Differentiation, U.S. National Library of Medicine, 1 Oct. 2015, pmc.ncbi.nlm.nih.gov/articles/PMC4590992/.
Hemann, Michael T, et al. “Evasion of the P53 Tumour Surveillance Network by Tumour-Derived Myc Mutants.” Nature, U.S. National Library of Medicine, 11 Aug. 2005, pubmed.ncbi.nlm.nih.gov/16094360/.
Hendriks, Rudi W, et al. “Targeting Bruton’s Tyrosine Kinase in B Cell Malignancies.” Nature Reviews. Cancer, U.S. National Library of Medicine, 14 Apr. 2014, pubmed.ncbi.nlm.nih.gov/24658273/.
Hu, S, et al. “Myc/BCL2 Protein Coexpression Contributes to the Inferior Survival of Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma and Demonstrates High-Risk Gene Expression Signatures: A Report from the International DLBCL RITUXIMAB-CHOP Consortium Program.” Blood, U.S. National Library of Medicine, 28 Feb. 2013, pubmed.ncbi.nlm.nih.gov/23449635/.
Itchaki, Gilad, and Jennifer R Brown. “The Potential of Venetoclax (ABT-199) in Chronic Lymphocytic Leukemia.” Therapeutic Advances in Hematology, U.S. National Library of Medicine, 8 July 2016, pubmed.ncbi.nlm.nih.gov/27695617/.
Kachur, Megan E., and Benjamin J. Rosen. “Educational Case: Anemia in a Neonate.” Academic Pathology, U.S. National Library of Medicine, 8 Apr. 2021, https://pubmed.ncbi.nlm.nih.gov/33889717/.
Kajtár B. “Lymphoma & related disorders Mature B cell neoplasms Small B cell lymphomas with a circulating component CLL / SLL.” PathologyOutlines.com website, 24 Apr. 2024, https://www.pathologyoutlines.com/topic/lymphomaCLL.html.
Karmali, Reem, et al. “Aggressive Disease Defined by Cytogenetics Is Associated with Cytokine Dysregulation in CLL/SLL Patients.” Journal of Leukocyte Biology, U.S. National Library of Medicine, Jan. 2013, pmc.ncbi.nlm.nih.gov/articles/PMC3525834/.
Karst, A M, and G Li. “Bh3-Only Proteins in Tumorigenesis and Malignant Melanoma.” Cellular and Molecular Life Sciences : CMLS, U.S. National Library of Medicine, Feb. 2007, pubmed.ncbi.nlm.nih.gov/17192811/.
Kastenhuber, Edward R, and Scott W Lowe. “Putting P53 in Context.” Cell, U.S. National Library of Medicine, 7 Sept. 2017, pmc.ncbi.nlm.nih.gov/articles/PMC5743327/.
KH, Kubbutat, et al. “Regulation of P53 Stability by MDM2.” Nature, U.S. National Library of Medicine, 15 May 1997, pubmed.ncbi.nlm.nih.gov/9153396/.
Klanova, Magdalena, and Pavel Klener. “Bcl-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas.” Cancers, U.S. National Library of Medicine, 10 Apr. 2020, pmc.ncbi.nlm.nih.gov/articles/PMC7226356/.
Kochenderfer, James N, et al. “Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor.” Journal of Immunotherapy (Hagerstown, Md. : 1997), U.S. National Library of Medicine, Sept. 2009, pubmed.ncbi.nlm.nih.gov/19561539/.
Kurland, John F., and William P. Tansey. “Myc-Mediated Transcriptional Repression by Recruitment of Histone Deacetylase.” Cancer Research, U.S. National Library of Medicine, 15 May 2008, pubmed.ncbi.nlm.nih.gov/18483244/.
LA, Donehower. “The P53-Deficient Mouse: A Model for Basic and Applied Cancer Studies.” Seminars in Cancer Biology, U.S. National Library of Medicine, 7 Oct. 1996, pubmed.ncbi.nlm.nih.gov/9110404/.
Lavrik, Inna, et al. “Death Receptor Signaling.” Journal of Cell Science, U.S. National Library of Medicine, 15 Jan. 2005, pubmed.ncbi.nlm.nih.gov/15654015/.
Lee, Daniel W, et al. “T Cells Expressing CD19 Chimeric Antigen Receptors for Acute Lymphoblastic Leukaemia in Children and Young Adults: A Phase 1 Dose-Escalation Trial.” Lancet (London, England), U.S. National Library of Medicine, 13 Oct. 2014, pubmed.ncbi.nlm.nih.gov/25319501/.
Leich, E, et al. “Follicular Lymphomas with and without Translocation T(14;18) Differ in Gene Expression Profiles and Genetic Alterations.” Blood, U.S. National Library of Medicine, 26 May 2009, pubmed.ncbi.nlm.nih.gov/19471018/.
Lindahl, Lise M, et al. “Stat5 Induces Mir-21 Expression in Cutaneous T Cell Lymphoma.” Oncotarget, U.S. National Library of Medicine, 19 July 2016, pmc.ncbi.nlm.nih.gov/articles/PMC5216756/.
Liu, Wei, et al. “Risk of Hepatitis B Reactivation Is Controllable in Patients with B-Cell Lymphoma Receiving Anti-Cd19 Car T Cell Therapy.” British Journal of Haematology, U.S. National Library of Medicine, 15 July 2020, pubmed.ncbi.nlm.nih.gov/32671820/.
Majid, A, et al. “BCL2 Expression in Chronic Lymphocytic Leukemia: Lack of Association with the BCL2 938A>C Promoter Single Nucleotide Polymorphism.” Blood, U.S. National Library of Medicine, 24 Oct. 2007, pubmed.ncbi.nlm.nih.gov/17959858/.
McCall, Robert K., et al. “Non-Nodal CD5-Negative Mantle Cell Lymphoma with Secondary TP53 Deletion.” Case Reports in Hematology, U.S. National Library of Medicine, 18 Mar. 2020, https://pubmed.ncbi.nlm.nih.gov/32257467/.
Merino, Delphine, et al. “Bh3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.” Cancer Cell, U.S. National Library of Medicine, 10 Dec. 2018, pubmed.ncbi.nlm.nih.gov/30537511/.
Mihalyova, Jana, et al. “Venetoclax: A New Wave in Hematooncology.” Experimental Hematology, U.S. National Library of Medicine, 2 Mar. 2018, pubmed.ncbi.nlm.nih.gov/29477371/.
Mithraprabhu, Sridurga, and Andrew Spencer. “Analysis of Circulating Tumor DNA.” Methods in Molecular Biology (Clifton, N.J.), U.S. National Library of Medicine, 2018, pubmed.ncbi.nlm.nih.gov/29797256/.
Molica, Stefano, et al. “External Validation on a Prospective Basis of a Nomogram for Predicting the Time to First Treatment in Patients with Chronic Lymphocytic Leukemia.” Cancer, U.S. National Library of Medicine, 7 Dec. 2012, pubmed.ncbi.nlm.nih.gov/23224939/.
Nowakowski, Grzegorz S, et al. “Using Smudge Cells on Routine Blood Smears to Predict Clinical Outcome in Chronic Lymphocytic Leukemia: A Universally Available Prognostic Test.” Mayo Clinic Proceedings, U.S. National Library of Medicine, 8 Apr. 2007, pubmed.ncbi.nlm.nih.gov/17418074/.
Ostojska, Magdalena, et al. “Car-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma.” Journal of Personalized Medicine, U.S. National Library of Medicine, 10 Nov. 2023, pmc.ncbi.nlm.nih.gov/articles/PMC10672004/#B111-jpm-13-01595.
Palma, Marzia, et al. “BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.” Frontiers in Immunology, U.S. National Library of Medicine, 1 July 2021, pubmed.ncbi.nlm.nih.gov/34276674/.
Perini, Guilherme Fleury, et al. “Bcl-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.” Current Treatment Options in Oncology, U.S. National Library of Medicine, 10 June 2021, pubmed.ncbi.nlm.nih.gov/34110507/.
Petros, AM, et al. “Solution Structure of the Antiapoptotic Protein Bcl-2.” Proceedings of the National Academy of Sciences of the United States of America, U.S. National Library of Medicine, 27 Feb. 2001, pubmed.ncbi.nlm.nih.gov/11248023/.
Poeschel, Viola, et al. “Four versus Six Cycles of Chop Chemotherapy in Combination with Six Applications of Rituximab in Patients with Aggressive B-Cell Lymphoma with Favourable Prognosis (Flyer): A Randomised, Phase 3, Non-Inferiority Trial.” Lancet (London, England), U.S. National Library of Medicine, 21 Dec. 2019, pubmed.ncbi.nlm.nih.gov/31868632/.
Prochownik, Edward V., and Huabo Wang. “Lessons in aging from Myc knockout mouse models.” Frontiers in Cell and Developmental Biology, U.S. National Library of Medicine, 9 Aug. 2023, https://pubmed.ncbi.nlm.nih.gov/37621775/.
Rai, K R, et al. “Clinical staging of chronic lymphocytic leukemia.” Blood, U.S. National Library of Medicine, Aug. 1975, https://pubmed.ncbi.nlm.nih.gov/1139039/.
Ramos, Carlos A, et al. “CD19-Car Trials.” Cancer Journal (Sudbury, Mass.), U.S. National Library of Medicine, 2014, pubmed.ncbi.nlm.nih.gov/24667955/.
Riches, John C, and John G Gribben. “Understanding the Immunodeficiency in Chronic Lymphocytic Leukemia: Potential Clinical Implications.” Hematology/Oncology Clinics of North America, U.S. National Library of Medicine, Jan. 2013, pubmed.ncbi.nlm.nih.gov/23561470/.
Rosales, Tilman, et al. “Partition of Myc into Immobile vs. Mobile Complexes within Nuclei.” Scientific Reports, U.S. National Library of Medicine, 2013, pubmed.ncbi.nlm.nih.gov/23739641/.
Sadelain, Michel. “Car Therapy: The CD19 Paradigm.” The Journal of Clinical Investigation, U.S. National Library of Medicine, 1 Sept. 2015, pubmed.ncbi.nlm.nih.gov/26325036/.
Sangle N, and Nat Pernick. “Anatomy & histology-lymph nodes.” PathologyOutlines.com website, 24 July 2025, https://www.pathologyoutlines.com/topic/lymphnodesanatomy.html.
Schmitt, C A, et al. “INK4A/ARF Mutations Accelerate Lymphomagenesis and Promote Chemoresistance by Disabling P53.” Genes & Development, U.S. National Library of Medicine, 15 Oct. 1999, pubmed.ncbi.nlm.nih.gov/10541553/.
Scott, DW, et al. “Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, U.S. National Library of Medicine, 10 Sept. 2015, pubmed.ncbi.nlm.nih.gov/26240231/.
Sears, R, et al. “Multiple Ras-Dependent Phosphorylation Pathways Regulate MYC Protein Stability.” Genes & Development, U.S. National Library of Medicine, 1 Oct. 2000, pubmed.ncbi.nlm.nih.gov/11018017/.
Sehn, L.H, et al. “Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma after Autologous Transplant: Full Results after Extended Follow‐up of the Phase 2 Checkmate 205 Trial - Fanale - 2017 - Hematological Oncology - Wiley Online Library.” Wiley Online Library, 7 June 2017, onlinelibrary.wiley.com/doi/full/10.1002/hon.2437_124.
Singh, Simar Pal, et al. “Role of Bruton’s Tyrosine Kinase in B Cells and Malignancies.” Molecular Cancer, U.S. National Library of Medicine, 19 Feb. 2018, pubmed.ncbi.nlm.nih.gov/29455639/.
SJ, Veis, et al. “BCL-2-Deficient Mice Demonstrate Fulminant Lymphoid Apoptosis, Polycystic Kidneys, and Hypopigmented Hair.” Cell, U.S. National Library of Medicine, 22 Oct. 1993, pubmed.ncbi.nlm.nih.gov/8402909/.
Smith, Victoria M, et al. “Specific Interactions of Bcl-2 Family Proteins Mediate Sensitivity to Bh3-Mimetics in Diffuse Large B-Cell Lymphoma.” Haematologica, U.S. National Library of Medicine, 10 Oct. 2019, pubmed.ncbi.nlm.nih.gov/31601689/.
Tagawa, H, et al. “Genome-Wide Array-Based CGH for Mantle Cell Lymphoma: Identification of Homozygous Deletions of the Proapoptotic Gene Bim.” Oncogene, U.S. National Library of Medicine, 17 Feb. 2005, pubmed.ncbi.nlm.nih.gov/15608680/.
Tari, Kaveh, et al. “Venetoclax Drug Increases the Apoptosis of T and B Acute Lymphoblastic Leukemia Cells by Reducing the Expression of Bcl-2.” International Journal of Molecular and Cellular Medicine, U.S. National Library of Medicine, 2023, pmc.ncbi.nlm.nih.gov/articles/PMC11092900/.
Thompson, Philip A, et al. “Fludarabine, Cyclophosphamide, and Rituximab Treatment Achieves Long-Term Disease-Free Survival in IGHV-Mutated Chronic Lymphocytic Leukemia.” Blood, U.S. National Library of Medicine, 22 Oct. 2015, pubmed.ncbi.nlm.nih.gov/26492934/.
Vidlarova, Monika, et al. “Recent Advances in Methods for Circulating Tumor Cell Detection.” International Journal of Molecular Sciences, U.S. National Library of Medicine, 15 Feb. 2023, https://pmc.ncbi.nlm.nih.gov/articles/PMC9959336/.
Vitolo, Umberto, et al. “Obinutuzumab or Rituximab plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, U.S. National Library of Medicine, 10 Aug. 2017, pubmed.ncbi.nlm.nih.gov/28796588/.
Wang, Haolan, et al. “Targeting P53 Pathways: Mechanisms, Structures, and Advances in Therapy.” Signal Transduction and Targeted Therapy, U.S. National Library of Medicine, 1 Mar. 2023, http://pubmed.ncbi.nlm.nih.gov/36859359/
Wang, Zhenguang, et al. “Current Status and Perspectives of Chimeric Antigen Receptor Modified T Cells for Cancer Treatment.” Protein & Cell, U.S. National Library of Medicine, 2 May 2017, pubmed.ncbi.nlm.nih.gov/28466386/.
Welcker, Markus, and Bruce E Clurman. “FBW7 Ubiquitin Ligase: A Tumour Suppressor at the Crossroads of Cell Division, Growth and Differentiation.” Nature Reviews. Cancer, U.S. National Library of Medicine, 8 Feb. 2008, pubmed.ncbi.nlm.nih.gov/18094723/.
Williams, Ashley B., and Bjorn Schumacher. “p53 in the DNA-Damage-Repair Process.” Cold Spring Harbor Perspectives in Medicine, U.S. National Library of Medicine, 2 May 2016, https://pubmed.ncbi.nlm.nih.gov/27048304/.
Xu-Monette, Zijun Y, et al. “Dysfunction of the TP53 Tumor Suppressor Gene in Lymphoid Malignancies.” Blood, U.S. National Library of Medicine, 19 Apr. 2012, pmc.ncbi.nlm.nih.gov/articles/PMC3335376/#sec1.
Xu-Monette, Zijun Y, et al. “Clinical and Biologic Significance of MYC Genetic Mutations in de Novo Diffuse Large B-Cell Lymphoma.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, U.S. National Library of Medicine, 15 July 2016, pmc.ncbi.nlm.nih.gov/articles/PMC4947447/#SD1.
Yoo, Kwai Han. “Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CT.” Blood Research, U.S. National Library of Medicine, 30 Apr. 2022, https://pmc.ncbi.nlm.nih.gov/articles/PMC9057662/.
Downloads
Posted
Categories
License
Copyright (c) 2025 Sam Mahdavy
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.